Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "RPA"

126 News Found

ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer
Clinical Trials | February 04, 2026

ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer

The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy


Virpax reports on progress of Envelta
Drug Approval | April 10, 2023

Virpax reports on progress of Envelta

Envelta is the company’s non-opioid pain product candidate for acute and chronic pain


Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData
News | December 07, 2022

Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData

The use of procalcitonin testing for sepsis management is highest in the US


China medical devices market to surpass $42 billion in 2022: GlobalData
News | July 10, 2022

China medical devices market to surpass $42 billion in 2022: GlobalData

Domestic devices are usually preferred over imported medical devices in the national or regional procurement.


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


Merck delivers resilient 2025 performance despite global headwinds
News | March 06, 2026

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results


Lupin tops world pharma and all Indian sectors in S&P ESG rankings
Sustainability | February 28, 2026

Lupin tops world pharma and all Indian sectors in S&P ESG rankings

Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally


Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive
News | January 29, 2026

Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive

The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities


Lupin receives highest ESG rating from CDP for climate change and water security
Sustainability | January 24, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability